Tanaka Capital Management Inc. acquired a new position in shares of BeyondSpring Inc. (NASDAQ:BYSI) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 21,322 shares of the company’s stock, valued at approximately $914,000. BeyondSpring comprises 2.1% of Tanaka Capital Management Inc.’s holdings, making the stock its 16th biggest position. Tanaka Capital Management Inc. owned about 0.10% of BeyondSpring at the end of the most recent quarter.

TRADEMARK VIOLATION WARNING: “Tanaka Capital Management Inc. Invests $914,000 in BeyondSpring Inc. (BYSI) Stock” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://theolympiareport.com/2017/10/12/tanaka-capital-management-inc-invests-914000-in-beyondspring-inc-bysi-stock.html.

A number of research analysts recently commented on the company. Maxim Group assumed coverage on BeyondSpring in a research note on Tuesday, August 22nd. They set a “buy” rating and a $52.00 price objective for the company. Zacks Investment Research upgraded BeyondSpring from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of BeyondSpring in a research note on Monday, August 21st. Finally, Rodman & Renshaw upped their price objective on BeyondSpring from $43.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, July 14th.

BeyondSpring Inc. (BYSI) traded down 0.53% on Thursday, hitting $38.99. The stock had a trading volume of 11,960 shares. The firm’s market cap is $890.69 million. The firm’s 50-day moving average price is $38.03 and its 200-day moving average price is $34.21. BeyondSpring Inc. has a 1-year low of $16.55 and a 1-year high of $48.49.

BeyondSpring Company Profile

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.